Cibus, Inc. (NASDAQ:CBUS - Get Free Report) Director Gerhard Prante sold 2,300 shares of the firm's stock in a transaction dated Monday, December 2nd. The stock was sold at an average price of $4.46, for a total value of $10,258.00. Following the transaction, the director now directly owns 66,357 shares in the company, valued at approximately $295,952.22. This represents a 3.35 % decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink.
Gerhard Prante also recently made the following trade(s):
- On Wednesday, November 27th, Gerhard Prante sold 1,150 shares of Cibus stock. The shares were sold at an average price of $4.50, for a total transaction of $5,175.00.
- On Monday, November 18th, Gerhard Prante sold 1,150 shares of Cibus stock. The shares were sold at an average price of $4.53, for a total transaction of $5,209.50.
Cibus Trading Down 7.0 %
CBUS stock opened at $4.39 on Wednesday. The firm has a 50 day moving average of $4.01 and a 200-day moving average of $7.20. Cibus, Inc. has a 12-month low of $2.86 and a 12-month high of $23.18. The company has a market cap of $116.16 million, a price-to-earnings ratio of -0.20 and a beta of 1.86.
Analysts Set New Price Targets
Strange: Why is Amazon suddenly yielding 39.70%?
From Investors Alley | Ad
Something big is happening with Amazon stock…
While most investors collect ZERO dividends from Amazon…
A small group just discovered a "backdoor" way to collect yields up to 39.70%!
Click here to see this breakthrough before everyone else →
CBUS has been the subject of a number of recent analyst reports. Canaccord Genuity Group restated a "buy" rating and issued a $20.00 price objective on shares of Cibus in a research report on Tuesday, October 22nd. HC Wainwright restated a "buy" rating and issued a $25.00 price objective on shares of Cibus in a research report on Monday, November 11th. Finally, Alliance Global Partners reduced their price target on shares of Cibus from $25.00 to $23.50 and set a "buy" rating for the company in a research report on Tuesday, September 24th.
View Our Latest Research Report on CBUS
Institutional Investors Weigh In On Cibus
A number of hedge funds and other institutional investors have recently modified their holdings of CBUS. Armistice Capital LLC acquired a new position in shares of Cibus during the 2nd quarter worth approximately $5,083,000. Vanguard Group Inc. raised its position in shares of Cibus by 3.7% during the 1st quarter. Vanguard Group Inc. now owns 721,945 shares of the company's stock worth $16,215,000 after purchasing an additional 26,017 shares during the last quarter. Rhumbline Advisers acquired a new position in shares of Cibus during the 2nd quarter worth approximately $221,000. FineMark National Bank & Trust raised its position in shares of Cibus by 24.3% during the 2nd quarter. FineMark National Bank & Trust now owns 20,488 shares of the company's stock worth $202,000 after purchasing an additional 4,000 shares during the last quarter. Finally, Bank of New York Mellon Corp acquired a new position in shares of Cibus during the 2nd quarter worth approximately $529,000. 33.81% of the stock is currently owned by institutional investors and hedge funds.
Cibus Company Profile
(
Get Free Report)
Cibus, Inc, a agricultural biotechnology company, develops and licenses plant traits to seed companies for royalties. The company primarily focus on trait productivity in two areas, including productivity traits that enable farmers to have higher yields and reduce the use of the crop protection chemicals and fertilizers; and sustainable ingredients that enable corporations to replace ingredients that are fossil fuel based or whose production results in increased greenhouse gases.
Read More
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. This story was reviewed by InsiderTrades.com's editorial team prior to publication. Please send any questions or comments about this story to [email protected].
